Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$244.28 USD

244.28
1,118,394

+1.81 (0.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

ResMed (RMD) Q3 Earnings and Revenues Beat Estimates

ResMed (RMD) delivered earnings and revenue surprises of 7.01% and 7.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.

EYE vs. RMD: Which Stock Should Value Investors Buy Now?

EYE vs. RMD: Which Stock Is the Better Value Option?

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.

Sheraz Mian headshot

Top Research Reports for Chevron, Novo Nordisk & Amgen

Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Novo Nordisk A/S (NVO) and Amgen Inc. (AMGN).

ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers

ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.

ESLOY vs. RMD: Which Stock Is the Better Value Option?

ESLOY vs. RMD: Which Stock Is the Better Value Option?

ResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls

ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.

ResMed (RMD) Q2 Earnings and Revenues Surpass Estimates

ResMed (RMD) delivered earnings and revenue surprises of 3.75% and 3.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Home Depot, Merck, Bank of America, Elevance Health and ResMed

Home Depot, Merck, Bank of America, Elevance Health and ResMed are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Home Depot, Merck & Bank of America

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Merck & Co., Inc. (MRK) and Bank of America Corporation (BAC).

ResMed (RMD) Q1 Earnings In Line, Operating Margin Falls

ResMed (RMD) continues to increase its access to semiconductor communications chips.

ResMed (RMD) Q1 Earnings Match Estimates

ResMed (RMD) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Landec (LNDC) Reports Q1 Loss, Tops Revenue Estimates

Landec (LNDC) delivered earnings and revenue surprises of -166.67% and 1.89%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Gains on Product Uptake Even as Expenses Rise

The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.

ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up

ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.

ResMed (RMD) Q4 Earnings Beat Estimates

ResMed (RMD) delivered earnings and revenue surprises of 0.68% and 0.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Derek Lewis headshot

ResMed Q4 Preview: Rebound Quarter Inbound?

RMD has primarily exceeded the Zacks Consensus EPS Estimate. However, the company registered an 8% bottom-line miss in its latest quarter.

Nephros Inc. (NEPH) Reports Q2 Loss, Tops Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 14.29% and 6.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Lags Q2 Earnings Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of -14.55% and 1.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) Q4 Earnings in Line, Revenues Beat Mark

AngioDynamics (ANGO) registers strong revenue growth in Med Tech and Med Device businesses, as well as in its GBUs, in fourth-quarter fiscal 2022.

Reasons Why You Should Invest in ResMed (RMD) Stock Now

Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.